Finvest
RCUS Biotechnology · Clinical stage · Oncology · RCC · Thesis updated July 19, 2026

Arcus is now a casdatifan bet

01 Running thesis

One main shot left

Arcus has moved past the shock of its anti-TIGIT failure and picked a new center of gravity: casdatifan. Casdatifan is a HIF-2α inhibitor, a drug meant to block a cancer survival pathway in clear cell renal cell carcinoma, the most common type of kidney cancer.

The bull case is clear but narrow. Arcus wants casdatifan to beat or outlast Merck's belzutifan and become a backbone drug across kidney cancer treatment lines. Merck's LITESPARK-012 failure may leave room for Arcus to test a front-line triplet of casdatifan, ipi, and an anti-PD-1 drug. Management has also pointed to a $5 billion to $10 billion peak sales opportunity for casdatifan.

The bear case is just as clear. Arcus is concentrating the company around one drug after domvanalimab failed. By 2027, management expects more than 80% of portfolio spend to go to casdatifan development. That focus can create value if the trials work, but it leaves little room for another late-stage miss.

Finn's score fits that setup. Performance gets credit for a funded plan and clear trial calendar, but valuation and overall score stay low because the company still burns cash, has no approved product, and now carries higher binary trial risk.

May 2026→Management laid out the new strategy after the anti-TIGIT failure: concentrate on casdatifan in clear cell kidney cancer and start moving the immune disease pipeline into the clinic.
May 2026▼Arcus discontinued STAR-121 for futility and said Gilead would not continue broad option rights to the early-stage pipeline after July 14, 2026. The company became a narrower bet on casdatifan.
Feb 2026▼The 2025 10-K showed STAR-221 was discontinued for futility, removing one of the major domvanalimab opportunities. Arcus also named the enacted U.S. BIOSECURE Act as a supply chain risk.
Oct 2025→Taiho exercised its option for casdatifan in Japan and certain Asian territories, which helped validate the asset. That was partly offset by an AstraZeneca-sponsored casdatifan combination study pausing recruitment over possible immune-related adverse events.
Aug 2025▲Gilead returned the etrumadenant license and Arcus said R&D expenses should peak in 2025 and decline in later years. That made the funding plan clearer.
May 2025→Arcus paused a potential Phase 3 path for etrumadenant in third-line colorectal cancer to focus resources on domvanalimab, casdatifan, and quemliclustat.
Feb 2025▲Gilead's option on the HIF-2α program expired, leaving Arcus with full global rights to casdatifan except for Taiho's territory option. That gave the company a clearer wholly owned late-stage asset.
Nov 2024▲Positive ARC-10 overall survival data supported the domvanalimab thesis at the time, and a new AstraZeneca collaboration added casdatifan validation. The same quarter also raised attention on Biosecure Act manufacturing risk.
02 Business model

Partner money, not drug sales

Arcus is not selling medicine today. In the first quarter of 2026, it reported $17 million of revenue, all from collaboration categories, not product sales. The two reported revenue lines were $12 million of license and development services revenue and $5 million of other collaboration revenue.

The old model leaned heavily on Gilead. That model has weakened because Gilead chose not to continue its broad option rights to Arcus's early-stage pipeline. Those rights end on July 14, 2026, so Arcus loses a key source of outside validation and possible future funding for new programs.

Management is trying to lower the cost base while funding the main bet. Arcus said it reduced headcount by about 10% and expects more than 80% of portfolio spend by 2027 to go toward casdatifan. As of March 31, 2026, the company had $876 million in cash, cash equivalents, and marketable securities, and its longer plan points to runway into the second half of 2028.

The business breaks if partners step back faster than costs fall, or if casdatifan data fail before the immune disease pipeline can show useful proof of concept.

03 Product portfolio

Casdatifan at the center

Growth engine

Casdatifan

Casdatifan is the main value driver. It is in the Phase 3 PEAK-1 study for second-line clear cell kidney cancer and is being tested in front-line combinations.

Option

Quemliclustat

Quemliclustat is a CD73 inhibitor in the fully enrolled Phase 3 PRISM-1 trial for pancreatic cancer. A readout in the first half of 2027 could add a second late-stage chance.

Option

AB102

AB102 is an oral MRGPRX2 antagonist for urticaria, a skin disease that causes hives. Arcus expects it to enter Phase 1 in Q3 2026 with early PK data shortly after.

Option

Oral TNF inhibitor

This is part of the new inflammation and immunology push. Arcus expects the program to enter the clinic in 2027.

Option

CCR6 antagonist

This is another oral immune disease candidate meant to diversify the company beyond cancer. It is also expected to enter the clinic in 2027.

Option

AB801

AB801 is an AXL inhibitor where Gilead still has existing time-limited rights. It is no longer part of a broad Gilead option package for Arcus's early-stage pipeline.

04 Business segments

Reported revenue lines

License and development services revenue71%declining
Other collaboration revenue29%declining

Arcus says it operates as one reportable segment. For the three months ended March 31, 2026, the mix below uses its two reported revenue categories, both tied to collaborations.

05 Risk factors

What can break the thesis

Casdatifan trial failure

High impact · Medium odds

Arcus is making casdatifan the main company bet. If PEAK-1 misses, or if front-line combination data look weak, the stock could lose its main growth story. The risk is larger because management expects more than 80% of portfolio spend by 2027 to go toward this drug.

We watchPEAK-1 enrollment completion in Q4 2026 and later efficacy, durability, and safety updates.

Front-line triplet safety

High impact · Medium odds

Arcus wants to test casdatifan with ipi and an anti-PD-1 drug in front-line kidney cancer. That could create a large market if it works, but three-drug cancer regimens can add side effects. A separate AstraZeneca-sponsored casdatifan combination study had paused recruitment in 2025 because of possible immune-related adverse events, so safety remains a key question.

We watchFall 2026 initial safety and primary progression data for casdatifan plus ipi plus anti-PD-1.

Partner pullback

Medium impact · High odds

Gilead chose not to keep broad option rights to Arcus's early-stage pipeline after July 14, 2026. That reduces future partner funding potential and weakens outside validation. Taiho still supports casdatifan in certain Asian territories, but the broad Gilead halo is smaller.

We watchNew licensing deals, option exercises, or partner exits after the Gilead option period ends.

BIOSECURE supply chain risk

Medium impact · Medium odds

Arcus has disclosed risk from U.S. actions that restrict work with Chinese biotech suppliers. WuXi Biologics in China has been a named manufacturing dependency for some Arcus assets. Even if the main clinical data are good, supply disruption could slow trials or raise costs.

We watchAny Arcus update on second-source manufacturers and implementation of the U.S. BIOSECURE Act.

Cash burn before proof

Medium impact · Medium odds

Arcus had $876 million of cash, cash equivalents, and marketable securities as of March 31, 2026, but it also lost $128 million in the first quarter. The runway is meaningful, yet biotech trials are expensive and failures can force a reset. New equity could dilute shareholders if the market does not reward the pipeline.

We watchQuarterly operating cash use, R&D spend, and any financing before major 2026 and 2027 readouts.
06 Quick answers

In one breath

Does Arcus Biosciences have approved drugs?

No. Arcus is still clinical stage, which means its drugs are being tested and are not yet approved for sale. Its reported revenue comes from collaborations, not product sales.

What is casdatifan?

Casdatifan is Arcus's HIF-2α inhibitor for clear cell renal cell carcinoma, a common form of kidney cancer. It is now the company's lead asset and the center of its strategy.

Why did the Arcus thesis change in 2026?

The anti-TIGIT program was discontinued after Phase 3 failures, and Gilead decided not to extend broad option rights to the early pipeline. Arcus then refocused around casdatifan and a newer inflammation and immunology pipeline.

What are the next key Arcus catalysts?

The next key items are PEAK-1 enrollment completion in Q4 2026, fall 2026 safety and early progression data for the casdatifan triplet, and AB102 entering Phase 1 in Q3 2026.